Study S000015

Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04885634
Acronym: SOCRATES-AF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2022-10
Primary completion: 2024-01
Lead sponsor: Axel Brandes
Conditions: Atrial Fibrillation; Overweight and Obesity
Interventions: DRUG:Semaglutide Injectable Product; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2021-002017-34

Registered primary outcomes

Number of Participants to Complete Recruitment [Up to 68 weeks, until end of treatment]
Number of Participants to Complete Follow-up [Up to 75 weeks, until final follow-up]
Total Resource Requirement [Up to 75 weeks, until final follow-up]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.